Your browser doesn't support javascript.
loading
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann, Michal; Murina, Olga; Reijns, Martin A M; Agathanggelou, Angelo; Challis, Rachel; Tarnauskaite, Zygimante; Muir, Morwenna; Fluteau, Adeline; Aregger, Michael; McEwan, Andrea; Yuan, Wei; Clarke, Matthew; Lambros, Maryou B; Paneesha, Shankara; Moss, Paul; Chandrashekhar, Megha; Angers, Stephane; Moffat, Jason; Brunton, Valerie G; Hart, Traver; de Bono, Johann; Stankovic, Tatjana; Jackson, Andrew P; Durocher, Daniel.
Affiliation
  • Zimmermann M; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Murina O; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Reijns MAM; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Agathanggelou A; Institute for Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Challis R; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Tarnauskaite Z; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Muir M; Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.
  • Fluteau A; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Aregger M; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • McEwan A; The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Yuan W; The Institute of Cancer Research, London, UK.
  • Clarke M; The Institute of Cancer Research, London, UK.
  • Lambros MB; The Institute of Cancer Research, London, UK.
  • Paneesha S; Heartlands Hospital, Birmingham, UK.
  • Moss P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Chandrashekhar M; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Angers S; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Moffat J; Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy & Department of Biochemistry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Brunton VG; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Hart T; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • de Bono J; Canadian Institute for Advanced Research, Toronto, Ontario, Canada.
  • Stankovic T; Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.
  • Jackson AP; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Durocher D; The Institute of Cancer Research, London, UK.
Nature ; 559(7713): 285-289, 2018 07.
Article in En | MEDLINE | ID: mdl-29973717
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleotides / DNA Damage / CRISPR-Cas Systems / Poly (ADP-Ribose) Polymerase-1 / Gene Editing / Neoplasms Type of study: Prognostic_studies Language: En Journal: Nature Year: 2018 Type: Article Affiliation country: Canada
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleotides / DNA Damage / CRISPR-Cas Systems / Poly (ADP-Ribose) Polymerase-1 / Gene Editing / Neoplasms Type of study: Prognostic_studies Language: En Journal: Nature Year: 2018 Type: Article Affiliation country: Canada